FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to pharmacy and oncology. Disclosed are a combination of an FGFR inhibitor selected from N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or its salt, solvate and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazole-4-yl)pyrido[2,3-b]pyrazine-6-amine or a salt thereof, a solvate and an IGF1R inhibitor for preventing or treating cancer, a composition of the same application comprising said combination, use thereof for preparing a medicinal agent for preventing or cancer treatment (embodiments), method of using them (embodiments) and a combined preparation of the same purpose.
EFFECT: technical result is a combination of said FGFR inhibitors with an inhibitor of IGF1R (according to examples - GSK1838705A, BMS-754807) blocks the development of primary resistance to the treatment of small cell lung cancer cells.
24 cl, 3 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| NEW COMPOUNDS | 2016 |
|
RU2747645C2 |
| METHOD OF TREATING AND PREVENTING TUMOUR WHICH IS AMENABLE TO ENDOCRINE THERAPY, USING COMBINED USE OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND ENDOCRINE THERAPY | 2019 |
|
RU2825636C2 |
| BIGETEROARYL-SUBSTITUTED 1,4-BENZODIAZEPINES AND WAYS OF THEIR USE FOR CANCER TREATMENT | 2016 |
|
RU2747644C2 |
| PTERIDINES AS FGFR INHIBITORS | 2013 |
|
RU2702906C2 |
| SUBSTITUTED QUINAZINE DERIVATIVES AS FGFR-KINASE INHIBITORS FOR TREATMENT OF CANCER | 2011 |
|
RU2602233C2 |
| BICYCLIC AMINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | 2007 |
|
RU2465275C2 |
| INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
| FGFR EXPRESSION AND SENSITIVITY TO FGFR INHIBITOR | 2016 |
|
RU2728674C2 |
| COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806625C2 |
